# US 2006/0069106 A1 · Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069106 A1
- Document ID: US20060069106A1
- Status: Published application
- Kind: A1
- Application number: 11/168,006
- Filed: 2005-06-27
- Published: 2006-03-30
- Earliest claimed: 2004-06-28
- Assignees: Amgen SF, LLC
- Inventors: Zice Fu; Michael Johnson; An-Rong Li; Andrew Marcus; Julio Medina; Philippe Bergeron; Xiaoqi Chen; Xiaohui Du; Jeffrey Deignan; Jason Duquette; Darin Gustin; Jeffrey Mihalic
- Web page: https://patentgrep.com/patent/US20060069106A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds are provided having the formula: wherein variables A1, A2, A3, A4, R1, R2, R3, R4, Q and L are as described herein. The subject compounds are useful for treatment of inflammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful for treatment of inflammatory and immune disorders and disease such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

## Claims

### Claim 1

A compound having the formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
Q is a member selected from the group consisting of —C(O)—, —CH2CO—, —CH2SO— and —CH2SO2—;
L is a bond or (C1-C5)alkylene;
A1, A2 and A3 are independently selected from the group consisting of C(R′)(R″) and C(O);
A4 is C(R′)(R″) or N(R′″);
each R′ and R″ is independently selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, fluoro(C1-C4)alkyl, aryl, heteroaryl, aryl(C1-C8)alkyl and heteroaryl(C1-C8)alkyl, optionally, R′ and R″ groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and R′ and R″ groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring;
R′″ is selected from the group consisting of hydrogen, (C1-C8)alkyl and (C2-C8)heteroalkyl;
R1 is heteroaryl or aryl;
R2 is selected from the group consisting of hydrogen, halogen, (C1-C10)alkyl, (C2-C10)heteroalkyl, hetero(C1-C10)cycloalkyl, (C1-C10)alkylaryl and (C2-C10)heteroalkylaryl, optionally R2 may be combined with L to form a 5-, 6-, 7- or 8-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S;
R3 is absent or is a member selected from the group consisting of —H, —CHR6R7, S(O)mR5, —S(O)mN(R8)R9, —S(O)mN(R8)CH2R6, —N(R8)SO2R5, —N(R8)CH2R10,
wherein
R5 is selected from the group consisting of (C1-C8)alkyl, (C2-C8)heteroalkyl, aryl and heteroaryl;
R6 and R7 independently are hydrogen, (C1-C8)alkyl or (C2-C8)heteroalkyl,
R8 is hydrogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, heteroaryl or aryl,
R9 is (C1-C8)alkyl;
R10 is aryl,
Z is CH or N,
X is a bond, (C1-C6)alkylene or (C1-C6)heteroalkylene,
Y is (C1-C6)alkylene;
the subscript m is 0, 1 or 2; and
optionally, R3 may be combined with R2 to form a 4-, 5-, 6-, 7- or 8-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, O and S; and
R4 is a member selected from the group consisting of (C1-C20)alkyl, (C2-C20)heteroalkyl, heteroaryl, aryl, heteroaryl(C1-C6)alkyl, heteroaryl(C2-C6)heteroalkyl, aryl(C1-C6)alkyl and aryl(C2-C6)heteroalkyl;
with the proviso that A4 is not NH when A1, A2 and A3 are CH2, R1 is 4-(2,2,2-trifluoroethoxy)phenyl, R2 is methyl, R3 is 3-picolyl and Q is C(O), -Q-R4 taken together is
and L is —CH2—.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is para-cyanophenyl.

### Claim 3 (depends on 1)

The compound of claim 1, having the formula (Ia):
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 4 (depends on 3)

The compound of claim 3, wherein A4 is N(R′″).

### Claim 5 (depends on 3)

The compound of claim 3, wherein A1, A2 and A3 are C(R′)(R″).

### Claim 6 (depends on 3)

The compound of claim 3, having the formula (II):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
each Ra is independently selected from the group consisting of halogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, fluoro(C1-C4)alkyl, aryl, heteroaryl, aryl(C1-C8)alkyl and heteroaryl(C1-C8)alkyl, optionally, Ra groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and Ra groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring; and
the subscript k is 0, 1, 2, 3 or 4.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R′″ is —CH3, —CH2CH3 or —C(O)CH3.

### Claim 8 (depends on 6)

The compound of claim 6, wherein k is 0.

### Claim 9 (depends on 6)

The compound of claim 6, having the formula (III):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is selected from the group consisting of hydrogen, (C1-C8)alkyl and (C2-C8)heteroalkyl.

### Claim 10 (depends on 3)

The compound of claim 3, wherein A4 is C(R′)(R″).

### Claim 11 (depends on 10)

The compound of claim 10, wherein A1, A2 and A3 are C(R′)(R″).

### Claim 12 (depends on 11)

The compound of claim 11, having the formula (IV):
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 13 (depends on 11)

The compound of claim 11, having the formula (V):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
each Ra is independently selected from the group consisting of halogen, (C1-C8)alkyl, (C2-C8)heteroalkyl, fluoro(C1-C4)alkyl, aryl, heteroaryl, aryl(C1-C8)alkyl and heteroaryl(C1-C8)alkyl, optionally, Ra groups on adjacent carbon atoms may be combined to form a 5- or 6-membered fused ring, and Ra groups attached to the same carbon atom may be combined to form a 3-8 membered spirocyclic ring; and
the subscript p is 0, 1, 2, 3 or 4.

### Claim 14 (depends on 13)

The compound of claim 13, having the formula (VI):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R11 is selected from the group consisting of hydrogen, (C1-C8)alkyl and (C2-C8)heteroalkyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R3 is a member selected from the group consisting of —H, —SO2CH3, —SO2CH2CH3,

### Claim 16 (depends on 4, 10)

The compound according to claim 4 or 10, wherein -L-R3 when taken together is

### Claim 17 (depends on 4, 10)

The compound of claim 4 or 10, wherein R1 is a unsubstituted or a meta- or para-substituted phenyl, wherein the substituting group is a halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, oxy(C1-C8)alkyl, or oxy(C1-C8)haloalkyl.

### Claim 18 (depends on 4, 10)

The compound of claim 4 or 10, wherein R1 is a meta- or para-substituted phenyl, wherein the substituting group is a cyano.

### Claim 19 (depends on 4, 10)

The compound of claim 4 or 10, wherein R2 is a member selected from the group consisting of

### Claim 20 (depends on 4, 10)

The compound of claim 4 or 10, wherein Q is —C(O)—.

### Claim 21 (depends on 4, 10)

The compound of claim 4 or 10, wherein L is a bond, —CH2— or —CH2CH2—.

### Claim 22 (depends on 4, 10)

The compound of claim 4 or 10, wherein -Q-R4 is

### Claim 23 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 24 (depends on 1)

A method of treating an inflammatory or immune condition or disease in a subject, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to claim 1.

### Claim 25 (depends on 24)

The method of claim 24, wherein said inflammatory or immune condition or disease is selected from the group consisting of neurodegenerative diseases, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, psoriasis, eczema, uticaria, type I diabetes, asthma, conjunctivitis, otitis, allergic rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Behcet's syndrome, gout, cancer, viral infections, bacterial infections, organ transplant conditions, skin transplant conditions and graft v. host disease.

### Claim 26 (depends on 25)

The method of claim 25, wherein said compound is administered in combination with a second therapeutic agent, wherein said second therapeutic agent is useful for treating neurodegenerative diseases, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, atherosclerosis, encephalitis, meningitis, hepatitis, nephritis, sepsis, sarcoidosis, psoriasis, eczema, uticaria, type I diabetes, asthma, conjunctivitis, otitis, allergic rhinitis, chronic obstructive pulmonary disease, sinusitis, dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Behcet's syndrome, gout, cancer, viral infections, bacterial infections, organ transplant conditions, skin transplant conditions or graft v. host disease.

### Claim 27 (depends on 25)

The method of claim 25, wherein said inflammatory or immune condition or disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, organ transplant conditions and skin transplant conditions.

### Claim 28 (depends on 25)

The method of claim 25, wherein said compound modulates CXCR3.

### Claim 29 (depends on 1)

A method for the modulation of CXCR3 function in a cell, comprising contacting said cell with a compound of claim 1.

### Claim 30 (depends on 1)

A method for the modulation of CXCR3 function, comprising contacting a CXCR3 protein with a compound of claim 1.
